Estimating the cost-effectiveness of daclatasvir plus asunaprevir in difficult to treat Japanese patients chronically infected with hepatitis C genotype 1b-Reference-Cited by-同舟云学术

Estimating the cost-effectiveness of daclatasvir plus asunaprevir in difficult to treat Japanese patients chronically infected with hepatitis C genotype 1b

Published:2015-10-06 Issue:5 Volume:46 Page:423-433
ISSN:1386-6346
Container-title:Hepatology Research
language:en
Short-container-title:Hepatol Res

Author:

McEwan Phil¹²,Ward Thomas¹,Webster Samantha¹,Yuan Yong³,Kalsekar Anupama³,Kamae Isao⁴,Kobayashi Masahiro⁵,Tang Ann⁶,Kumada Hiromitsu⁵

Affiliation:

1. Health Economics and Outcomes Research; Monmouth Wales UK

2. Center for Health Economics; Swansea University; Cardiff Wales UK

3. World Wide Health Economics and Outcomes Research; Bristol-Myers Squibb Pharmaceuticals; Princeton New Jersey USA

4. Graduate School of Public Policy; The University of Tokyo; Tokyo Japan

5. Department of Hepatology; Toranomon Hospital; Tokyo Japan

6. Health Economics and Outcomes Research; Bristol-Myers K.K.; Tokyo Japan

Publisher

Wiley

Subject

Infectious Diseases,Hepatology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/hepr.12570/fullpdf

Reference39 articles.

1. EASL Clinical Practice Guidelines: management of hepatitis C virus infection;European Association for the Study of the Liver;J Hepatol,2014

2. Global epidemiology of hepatitis C virus infection;Shepard;Lancet Infect Dis,2005

3. Epidemiology and clinical aspects on hepatitis C;Higuchi;Jpn J Infect Dis,2002

4. Cost-effectiveness of ribavirin plus interferon alpha-2b for either interferon relapsers or non-responders in chronic hepatitis C: a Japanese trial;Ishida;Hepatol Res,2004

5. Changing trends in hepatitis C infection over the past 50 years in Japan;Chung;Intervirology,2010

Cited by 21 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cost-effectiveness of a “treat-all” strategy using Direct-Acting Antivirals (DAAs) for Japanese patients with chronic hepatitis C genotype 1 at different fibrosis stages;PLOS ONE;2021-04-01

2. Estimating the price at which hepatitis C treatment with direct-acting antivirals would be cost-saving in Japan;Scientific Reports;2020-03-05

3. Estimating the cost‐effectiveness of screening for hepatitis C virus infection in Japan;Hepatology Research;2020-01-22

4. Healthcare Expenditures for the Treatment of Patients Infected with Hepatitis C Virus in Japan;PharmacoEconomics;2019-11-25

5. Cost-effectiveness analysis of lenvatinib treatment for patients with unresectable hepatocellular carcinoma (uHCC) compared with sorafenib in Japan;Journal of Gastroenterology;2019-02-20